The ADA Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population in which the adenosine deaminase (ADA) gene has been disrupted in the human HT29 colorectal adenocarcinoma cell line. This loss-of-function model is designed for investigations into adenosine metabolism and signaling within an epithelial cancer context. The polyclonal format provides a heterogeneous population of ADA-disrupted cells suitable for assaying diverse genetic alterations and phenotypic outcomes without isolation of single-cell clones.
The HT29 cell line, originally derived from a 44-year-old female Caucasian with colorectal adenocarcinoma, is an established model for intestinal differentiation, drug absorption, and colorectal cancer research. These cells harbor characterized mutations, including p53 R273H and an APC frameshift (c.3204insA), and upon appropriate treatment, they can differentiate into enterocyte-like cells, exhibiting brush border morphology and polarized organization. This background permits studies linking ADA function to colon cancer biology and differentiated intestinal phenotypes.
ADA is a critical enzyme in purine metabolism, catalyzing the irreversible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine. Its expression is regulated by the c-Myb transcription factor, methylation, and interferon-gamma. Key downstream components include inosine, reduced adenosine levels, and the adenosine receptors ADORA1, ADORA2A, ADORA2B, and ADORA3, as well as decreased dATP accumulation. ADA interacts with adenosine, deoxyadenosine, CD26 (DPP4), and ADA complexing protein 2 (ADCP2). Mechanistically, ADA deficiency results in accumulation of adenosine and deoxyadenosine, which are phosphorylated to toxic dATP, inhibiting ribonucleotide reductase and impairing DNA synthesis and repair, with pronounced effects on lymphocyte development and, potentially, on adenosine receptor-mediated signaling in HT29 cells.
In the context of the HT29 colorectal cancer model, ADA disruption can alter the balance of adenosine and its downstream signaling pathways, which are known to influence cell proliferation, migration, and differentiation. Since HT29 cells can differentiate into enterocytes, this knockout model enables exploration of how purine metabolism intersects with intestinal cell maturation and barrier function. The interplay between ADA loss and the tumor microenvironment, particularly through adenosine receptor engagement, may provide insights into immune evasion mechanisms and the cross-talk between cancer cells and immune signals originally characterized in SCID pathophysiology.
This polyclonal knockout product is suited for a range of applications, including quantification of ADA enzymatic activity, adenosine measurement by HPLC, and western blotting for ADA protein. Researchers can employ RT-qPCR to assess adenosine receptor expression, MTS/MTT assays for cell proliferation, transwell assays for migration and invasion, and TEER measurements to evaluate barrier integrity. Flow cytometry for CD26, phospho-signaling analysis, and drug sensitivity assays further enable mechanistic studies and therapeutic testing in adenosine-related colorectal cancer or SCID-modeling contexts. For further technical details and support, please contact Ascent Research.
